Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib-Reference-Cited by-同舟云学术

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

Published:2015-08 Issue:8 Volume:5 Page:e338-e338
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Kumar S K,LaPlant B,Roy V,Reeder C B,Lacy M Q,Gertz M A,Laumann K,Thompson M A,Witzig T E,Buadi F K,Rivera C E,Mikhael J R,Bergsagel P L,Kapoor P,Hwa L,Fonseca R,Stewart A K,Chanan-Khan A,Rajkumar S V,Dispenzieri A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201560.pdf

Reference21 articles.

1. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947–959.

2. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84: 1095–1110.

3. Adams J . Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9–16.

4. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420–4427.

5. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557–3560.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation;JCO Precision Oncology;2024-07

2. Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022;Pharmaceuticals;2024-06-21

3. Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma—Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries;International Journal of Molecular Sciences;2024-06-11

4. A comparative study of boron-containing and boron-omitted capsaicinoids;CAN J CHEM;2024

5. RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma;Frontiers in Immunology;2023-11-15